ClinicalTrials.gg
CompletedNCT02955693LAS41008Updated Dec 22, 2016

Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008

A Phase 1 interventional study of LAS41008 120 mg / Fumaderm® 120 mg in Psoriasis, sponsored by Almirall, S.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-22.

Sponsored by Almirall, S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Psoriasis by Almirall, S.A. — 2 open to participants now, 3 under way, none of them phase 3. Psoriasis · Almirall, S.A..

Enrollment
8th of 14
32 · median 36
Started
2016
the only one that year
Phase 1
Only one
of the 20
Registered
10th of 20
by date

Among the 20 studies in Psoriasis by Almirall, S.A., this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2016, is the only one in phase 1, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 20 studies in Psoriasis by Almirall, S.A. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Psoriasis by Almirall, S.A., or all of them as a file.
02

Study summary

The purpose of this study is to determine how the organism affects MMF (metabolite of dimethyl fumarate [DMF]) after single oral dose administration of LAS41008 120 mg gastroresistant tablet and Fumaderm® 120 mg gastro-resistant tablet under fasting and fed conditions. The study also aims to assess the safety of the study treatments.

Read the detailed description

The present study will be conducted to further investigate the pharmacokinetics (PK) of LAS41008 (containing DMF) after single oral dose administrations of a 120 mg gastro-resistant tablet under fed and fasting conditions.

Two previous Phase 1 studies allowed exploring the PK of LAS41008 30 mg and 120 mg separately after multiple dosing. In the current study, an improved bioanalytical method will allow the detection of lower MMF concentrations, and thus the same gastro-resistant tablet formulation (LAS41008) as used in the previous Phase 1 study will be investigated, but on a larger population and after single oral dose administration. Only the higher LAS41008 dose (120 mg) will be tested, as this is the formulation to be most frequently used during a standard treatment course for psoriasis with LAS41008. Similarly, single oral doses of Fumaderm® 120 mg (defined mixture of DMF and calcium (Ca), magnesium (Mg), and zinc (Zn) salts of ethylhydrogenfumarate (EHF, mono-ethyl fumarate (MEF)) will be tested in order to provide better comparative PK data. The comparison of LAS41008 and Fumaderm® PK will be evaluated in an exploratory manner.

The study will be conducted according to a randomised, open-label, four-way complete crossover, single dose design in 32 healthy male and female subjects. Up to 4 discontinued subjects may be replaced in case of early dropouts or a dropout rate greater than 15% (5 or more subjects). Gender balance will also be taken into consideration to ensure that roughly the same number of males and females are randomised. Upon inclusion into the treatment phase, each subject will be randomly allocated to one of four treatment sequences in a 4x4 Williams design. On Day 1 of each treatment period subjects will receive a single oral dose of either LAS41008 120 mg gastro-resistant tablet or Fumaderm® 120 mg gastro-resistant tablet under fasting or fed conditions. The drug administrations will be separated by a wash-out-phase of 7 ± 3 days. Blood sampling for PK will be performed until 24 hours after each study drug administration.

The Informed Consent Form (ICF) will be signed before any study activity, including the withdrawal of any concomitant medication (at least 2 weeks before this screening visit) if required for study participation. The Screening Visit will take place within 28 days before randomisation and after signing of the ICF to check subjects' eligibility. In each period, subjects will be admitted to the study centre from the morning of Day -1 until discharge in the morning of Day 2 (after collection of last blood sampling for PK).

The duration of study participation for each subject from Visit 1 (Screening) to the Follow-up Visit 7 ± 3 days after the last study drug administration is estimated to be approximately 7 to 10 weeks considering study visits time-window allowance.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Pharmacokinetics
  • Healthy volunteers
  • Monomethylfumarate
  • Dimethyl fumarate
  • Fumaderm®
  • Ethyl fumarate
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to understand and follow instructions during the study as determined by the Investigator.
  • Signed and dated .
  • Men and women of any ethnic origin between 18 and 55 years of age (inclusive, at the time of Screening) in general good physical health as determined by medical and surgical history, physical examination, , vital signs, and clinical laboratory tests (including changes in laboratory test).
  • Weight within the normal range according to accepted values for the (BMI) within 18.0 to 29.0 kg/m2 (inclusive, at the time of Screening), and a body weight of at least 50 kg.
  • Normal blood pressure (Systolic Blood Pressure ≥ 90, ≤ 139 mmHg; Diastolic Blood Pressure ≥ 55, ≤ 89 mmHg) measured after at least 5 minutes rest in supine position.
  • A pulse rate of ≥ 45 and ≤ 99 beats per minute measured after at least 5 minutes rest in supine position.
  • ECG recording, in triplicate, taken at least 1 minute apart; after at least 5 minutes of rest in a supine position without clinically significant abnormalities.

Exclusion criteria

Exclusion Criteria:

  • Subject who has received (s) within 4 weeks of Day 1 or plan to receive a vaccination during the study until 6 months after the last dose of study medication.
  • More than moderate smoker (> 10 cigarettes/day).
  • Demonstrating excess in xanthine consumption (more than five cups of coffee or equivalent per day).
  • More than moderate alcohol consumption (subjects will be advised to consume no more than 2 units of alcohol per day and completely abstain from 72 hours prior to any visit (1 unit is equal to approximately 10 g of pure alcohol [250 mL] of beer [5%], 1 small glass [100 mL] of wine [12%] or 35 mL of spirits [35%]).
  • Any history of alcohol or drug abuse or excessive intake of alcohol, as judged by the Investigator.
  • Any history of drug , asthma (with the exception of childhood asthma), urticaria or other severe allergic diathesis as well as active hay fever.
  • Any history of hypersensitivity or lack of tolerability to the ingredients of the medicinal product (IMP).
  • Having febrile or infectious illness within at least 7 days prior to the Visit 1 (Screening) and Day -1 of Period 1.
  • Any presence of acute or chronic liver or renal diseases.
  • Any history or presence of gastrointestinal disease or problems including chronic gastritis, peptic ulcers, diarrhoea, or inflammatory bowel disease.
  • Any history of chronic or recurrent metabolic, pulmonary, neurological (especially history of epileptic seizures), endocrinological, immunological, psychiatric or cardiovascular disease, myopathies, and bleeding tendency.
  • Subjects who have ever received treatment (excluding topical or oral taken 1 and 5 years before Visit 1 [Screening] respectively).
  • Any history of frequent headache or migraine.
  • Any history of (excluding basal skin cell cancer), as judged by the Investigator.
  • Non-vasectomised man not using barrier during the study.
  • Nursing (breastfeeding) woman.
  • Women with a positive serum pregnancy test at Visit 1 (Screening) or a positive urine pregnancy test on Day -1 of each Period or women of not using one highly effective method of birth control in combination with a barrier method during the study.
  • Vegetarians.
  • Unable or unwilling to comply with the dietary conditions in this study.
  • Blood donation of more than 500 mL within 60 days prior to Visit 1 (Screening) or Day -1 of Period 1.
  • Participation in the treatment phase of a clinical study within 90 days (or five half-life times, whichever is longer) prior to Visit 1 (Screening).
  • Any abnormal safety laboratory values considered clinically significant by the Investigator, especially serum creatinine, alkaline phosphatase (AP), triglycerides or cholesterol, or medically relevant changes in haematology (especially differential cell count and ), or relevant observations of protein in urine.
  • Subjects with lymphocyte and white blood cell counts below the lower normal range (1.2 x 10\^9L and 3.0 x 10\^9L, respectively) or eosinophils above the upper normal range (0.4 x 10\^9L) will not be included in the study.
  • Liver enzyme results ( (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT)) above the (ULN female/male: AST: 31/37 IU/L; ALT: 35/50 IU/L; GGT: 42/71 IU/L).
  • Creatinine values above the upper limit of normal and an estimated below 90 mL/min.
  • Positive test for (HIV) antibodies and antigen. Positive virus surface antigen (HBsAg) test.
  • Positive Anti- virus antibodies (Anti-HCV) test.
  • Any history or suspicion of barbiturate, amphetamine, benzodiazepine, cocaine, opiates and cannabis abuse within the last 12 months (verified on-site by a urine test).
  • Subject is not willing to refrain from xanthine-containing food or beverages as well as grapefruit products within 48 hour prior to first administration until discharge.
  • Any gastrointestinal complaints within seven days prior to Visit 1 (Screening) or first study drug administration.
  • Use of any medication (over the counter or prescription medication) within two weeks prior to Visit 1 (Screening) and Day -1 of Period 1 (or at least 10 times the respective elimination halflife, whichever is longer). Paracetamol may be concomitantly used, at the discretion of the Investigator (up to 1000 mg per day).
  • Demonstrating any other active physical or mental disease, acute or chronic.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Other
    Sequence A (n=8)

    Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)

    Drug: LAS41008 120 mg / Fumaderm® 120 mg

  • Other
    Sequence B (n=8)

    LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)

    Drug: LAS41008 120 mg / Fumaderm® 120 mg

  • Other
    Sequence C (n=8)

    Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)

    Drug: LAS41008 120 mg / Fumaderm® 120 mg

  • Other
    Sequence D (n=8)

    LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)

    Drug: LAS41008 120 mg / Fumaderm® 120 mg

Interventions

  • DrugLAS41008 120 mg / Fumaderm® 120 mg

    Drug page: Dimethyl Fumarate

    Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period

    Also known as: LAS41008: DMF / Fumaderm®: DMF + Ca, Mg and Zn salts of EHF

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from zero to time t (AUC(0-t)) of LAS41008 120 mg/Fumaderm® 120 mg

    t is the time of the last concentration measured

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

  2. Cmax of LAS41008 120 mg/Fumaderm® 120 mg

    Maximum plasma concentration

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

  3. tmax of LAS41008 120 mg/Fumaderm® 120 mg

    Time to reach maximum plasma concentration

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

  4. tlag of LAS41008 120 mg/Fumaderm® 120 mg

    Lag time

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

Secondary outcomes

  1. Area under the concentration-time curve from zero to infinity (AUC) of LAS41008 120 mg/Fumaderm® 120 mg

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

  2. Extrapolated part of AUC (%AUCext) of LAS41008 120 mg/Fumaderm® 120 mg

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

  3. t1/2 of LAS41008 120 mg/Fumaderm® 120 mg

    Elimination half-life

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

  4. Formation clearance of a drug to a metabolite (CL/f) of LAS41008 120 mg/Fumaderm® 120 mg

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

  5. Vz/f of LAS41008 120 mg/Fumaderm® 120 mg

    Apparent volume of distribution during terminal phase after non-intravenous administration

    Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)

Other outcomes

  1. Blood pressure

    Time frame: at Visit 1 (screening), 1 hour pre-dose and approximately at the same time on Day 2 of each period

  2. Pulse rate

    Time frame: at Visit 1 (screening), 1 hour pre-dose and approximately at the same time on Day 2 of each period

  3. Oral body temperature

    Time frame: at Visit 1 (screening) and pre-dose on Day 1 of each period

  4. 12-lead electrocardiogram (ECG) parameters

    Time frame: on Day 2 of each period

  5. Physical examination findings

    Time frame: abbreviated on each admission and Day 2 of Period 4, and complete at Visit 1 (screening) and at the Follow-up Visit (7 ± 3 days after the study drug administration of the last treatment period)

  6. Safety laboratory tests values (standard haematology, blood chemistry [clinical chemistry], urinalysis [sediment], and pregnancy test)

    Note: Serum pregnancy test at Visit 1 (screening) and Follow-Up Visit; urine pregnancy test pre-dose

    Time frame: at Visit 1 (screening) and on Day 2 of each period, and at the Follow-Up Visit (7 ± 3 days after the study drug administration of the last treatment period)

  7. Overall tolerability (number of participants with adverse events (AEs) at the Follow-up Visit)

    Time frame: Follow-up Visit (7 ± 3 days after the study drug administration of the last treatment period)

  8. Number of participants with adverse events/serious adverse events (SAEs)

    Time frame: from signature of the informed consent until the Follow-up Visit (7 ± 3 days after the study drug administration of the last treatment period)

07

Study locations

1 site
  • Almirall Investigational Site #1
    London, Harrow HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Oct 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2016
First posted
Nov 4, 2016
Start
Sep 2016
Primary completionActual
Oct 2016
CompletionActual
Nov 2016
Last update
Dec 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02955693
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Nov 4, 2016
Start date
Sep 2016
Primary completion
Oct 2016
Completion
Nov 2016
Last update
Dec 22, 2016

Study contacts

Wolf-Godehard Ocker, MD
study director · Almirall Hermal GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion